Archives of Ophthalmology · 1989 · 13 citations · 26 references
MedicineCancer BiologyOncologyCancer PharmacologyMolecular OncologyRadiobiologyCell Cycle PharmacologyCellular Radiation ResponseMalignant NeoplasmsRadiation TherapyUveal MelanomaCell Death AssaysCell Death DetectionHistologic RegressionHyperthermiaTumor RadiosensitivityTumor Regression Assessment
Assessment of uveal melanoma response after many nonenucleation therapies is difficult with current modalities, since tumor regression is usually delayed. The goal of most treatments, including ionizing radiation or radiation and adjunct hyperthermia, is to destroy the reproductive capacity of the tumor. Cell cycling analysis with bromodeoxyuridine, a thymidine analogue only incorporated during DNA synthesis, was a useful indication of tumor control after hyperthermia was used to treat a Greene intraocular melanoma model. Cell cycling decreased from a mean of 16% before therapy to less than 1% in all the successfully treated tumors. Cell cycling changes preceded histologic evidence of cell death. In contrast, tumors that grew after insufficient treatment had increased cell cycling to a mean of 25%. Cell cycling studies with bromodeoxyuridine represent a sensitive gauge of the reproductive integrity of the tumor.
26
Radiotherapy for malignant melanoma of the choroid.
H. B. Stallard · British Journal of Ophthalmology · 1966 · 251 citations · Full text
Medicine, Ophthalmology, Surgery +12
Long-term Results of Proton Beam Irradiated Uveal Melanomas
Evangelos S. Gragoudas, Johanna M. Seddon, Kathleen M. Egan et al. · Ophthalmology · 1987 · 224 citations
Evangelos S. Gragoudas, Michael Goitein, Lynn Verhey et al. · Ophthalmology · 1980 · 220 citations
The effect of hyperthermia on vascular function, pH, and cell survival.
C. W. Song, M. S. Kang, Juong G. Rhee et al. · Radiology · 1980 · 210 citations
Effects of hyperthermia on normal and tumor microenvironment.
Haim I. Bicher, Fred W. Hetzel, Taljit S. Sandhu et al. · Radiology · 1980 · 202 citations
Medicine, Cancer Biology, Oncology +16